HAX’s VC-Founder Industry Hard Tech Matchup is now accepting applications. Register today!

Metabolomic Diagnostics

Diagnostic assay that predicts preeclampsia in pregnancy


Diarmuid Cahalane


Charles Garvey


Robin Tuytten

CEO & Co-Founder

Paul Hands


Company details

Metabolomic Diagnostics offers a revolutionary blood test to be administered at 15 weeks into a pregnancy that can accurately predict the risk that a woman will develop pre-eclampsia later in pregnancy. A combination of metabolites in the blood is measured and the results, along with certain clinical data, are fed into a classification algorithm, which extrapolates the results. This information will allow clinicians to tailor specific medical care to patients who are at higher risk of developing pre-eclampsia.

Get In Touch with Metabolomic Diagnostics

Please tell us a little bit about yourself and why you'd like to get connected. Metabolomic Diagnostics + SOSV will follow up with you via email.


No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.